Summary
Elevance Health, Inc. (then known as WellPoint, Inc.) filed this Form 8-K on May 7, 2012, to report the closing of a significant debt offering. The company successfully issued $850 million of 3.125% Notes due 2022 and $900 million of 4.625% Notes due 2042, for an aggregate principal amount of $1.75 billion. The net proceeds from this offering, approximately $1.72 billion after deducting expenses, are intended for general corporate purposes, including working capital and the repayment of existing debt. This debt issuance enhances the company's financial flexibility and is a strategic move to manage its capital structure. Investors should note the specific terms of these new notes, including their maturity dates, interest rates, redemption provisions, and the conditions under which the company would be required to repurchase them in the event of a change of control coupled with a credit rating downgrade. The filing also provides details on the underwriting agreement and the indenture governing these notes.
Key Highlights
- 1WellPoint, Inc. completed a debt offering of $850 million in 3.125% Notes due 2022 and $900 million in 4.625% Notes due 2042, totaling $1.75 billion in aggregate principal.
- 2Net proceeds of approximately $1.72 billion were raised after underwriting discounts and offering expenses.
- 3Proceeds are designated for working capital and general corporate purposes, including the repayment of short-term and long-term debt.
- 4The notes are governed by an Indenture dated January 10, 2006, with The Bank of New York Mellon Trust Company, N.A. as trustee.
- 5The 2022 Notes mature on May 15, 2022, and the 2042 Notes mature on May 15, 2042.
- 6The company has the option to redeem the notes early, with specific pricing formulas based on the Treasury Rate plus a spread.
- 7A "change of control" event, combined with a credit rating downgrade of the notes below investment grade by major rating agencies, triggers a mandatory purchase offer to noteholders at 101% of the principal amount plus accrued interest.